Humacyte, Inc.·4

May 26, 5:05 PM ET

Prichard Heather Ledbetter 4

4 · Humacyte, Inc. · Filed May 26, 2023

Insider Transaction Report

Form 4
Period: 2023-05-24
Prichard Heather Ledbetter
Chief Operating Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2023-05-25$1.19/sh+64,990$77,33874,179 total
  • Exercise/Conversion

    Stock Options (right to buy)

    2023-05-2564,9900 total
    Exercise: $1.19From: 2016-11-22Exp: 2023-11-22Common Stock (64,990 underlying)
  • Exercise/Conversion

    Common Stock

    2023-05-24$1.19/sh+13,789$16,40922,978 total
  • Sale

    Common Stock

    2023-05-25$3.83/sh9,613$36,81864,566 total
  • Exercise/Conversion

    Stock Options (right to buy)

    2023-05-2413,78964,990 total
    Exercise: $1.19From: 2016-11-22Exp: 2023-11-22Common Stock (13,789 underlying)
  • Sale

    Common Stock

    2023-05-24$4.14/sh13,789$57,0869,189 total
Footnotes (2)
  • [F1]The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.14 to $4.16. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F2]The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.82 to $3.89. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Documents

1 file
  • 4
    tm2317123-10_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT